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Abstract
The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary
Stroke Prevention in Sickle Cell Anemia (STOP 2) trials established routine trans-
cranial Doppler ultrasound (TCD) screening, with indefinite chronic red cell transfu-
sions (CRCT) for children with abnormal TCD as standard of care. Implementation
failures and limitations to the STOP protocol may contribute to continued ischemic
stroke occurrence. In the “Post-STOP” study, we sought to assess the impact of the
STOP protocol on the incidence of ischemic stroke in a multicenter cohort of former
STOP and/or STOP 2 trial participants. A central team abstracted data for 2851
(74%) of the 3835 children who took part in STOP and/or STOP 2. Data included
TCD and neuroimaging results, treatment, laboratory data, and detailed clinical infor-
mation pertaining to the stroke. Two stroke neurologists independently confirmed
each stroke using pre-specified imaging and clinical criteria and came to consensus.
Among the 2808 patients who were stroke-free at the start of Post-STOP with avail-
able follow-up, the incidence of first ischemic stroke was 0.24 per 100 patient-years
(95% CI, 0.18, 0.31), with a mean (SD) duration of follow-up of 9.1 (3.4) [median
10.3, range (0-15.4)] years. Most (63%) strokes occurred in patients in whom the
STOP protocol had not been properly implemented, either failure to screen appropri-
ately with TCD (38%) or failure to transfuse adequately patients with abnormal TCD
(25%). This study shows that substantial opportunities for ischemic stroke prevention
remain by more complete implementation of the STOP Protocol.
1 | INTRODUCTION
Stroke is one of the most devastating complications of sickle cell dis-
ease (SCD). In an unscreened population in the Cooperative Study of
Sickle Cell Disease (CSSCD), the overall incidence of first stroke in
individuals with homozygous sickle cell disease (SCD-SS) was 0.61 per
100 patient years.1 Subsequently, the Stroke Prevention Trial in Sickle
Cell Anemia (STOP) found that routine transcranial Doppler (TCD)
ultrasound screening with chronic red cell transfusions (CRCT) for
children with abnormal TCD, reduced the risk of first stroke by over
90% in this high risk group.2 The follow-up study, Optimizing Primary
Stroke Prevention in Sickle Cell Anemia (STOP 2), showed that dis-
continuation of CRCT was associated with an unacceptably high rate
of reversion to high risk of stroke, which led to the recommendation
of indefinite transfusion therapy for patients with abnormal TCD.3
The STOP protocol includes annual TCD screening for children with
SCD-SS and SCD-S-Beta0-thalassemia from ages 2 to 16 years, with
more frequent monitoring if the result is not normal. Treatment
with CRCT is recommended for children identified with abnormal TCD.
The success of this screening and treatment strategy has been re-
demonstrated in several clinical series.4,5 Analyses of large administra-
tive databases also show a reduction in hospitalizations with stroke
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diagnostic codes, when comparing time periods before and after the
publication of the STOP study in 1998.6,7 Yet TCD screening and CRCT
often are underutilized, and limitations of the STOP protocol also may
lead to the occurrence of stroke in this patient population.4
To assess the impact of the STOP protocol on stroke incidence,
we sought to determine the rate of centrally-confirmed ischemic
stroke in a multicenter cohort of former STOP and/or STOP 2 trial
participants and to assess whether these strokes were due to failures
of STOP protocol implementation or to limitations of the STOP proto-
col itself (defined as false negative TCD screening or CRCT treatment
failures). We hypothesized that the overall rate of ischemic stroke
would be lower than prior to the publication of STOP, and that most
strokes would be due to STOP protocol implementation failures.
These data will help direct appropriate modifications to the STOP pro-
tocol and its implementation.
2 | METHODS
Institutional Review Board approval was obtained from the participat-
ing sites. Informed consent or a waiver of consent was obtained based
on local requirements.
2.1 | STOP and STOP 2 studies
Between 1995 and 2005, STOP and STOP 2 were conducted at 26 sites
in the US and Canada. These studies included 3835 children, ages 2 to
16 years with SCD type SS or S-beta0-thalassemia. All children under-
went at least a single TCD with classification of results as previously
described.2 A subset of these children participated in an ancillary study
with repeated TCD screening. Data on stroke were collected on
screened subjects for the duration of the study (1995-2000).8 In the
STOP study, children with abnormal TCD were eligible for randomiza-
tion to CRCT or usual care.2 In the STOP 2 study, children with prior
abnormal TCD, whose TCD had reverted to normal on CRCT were eli-
gible for randomization to continued CRCT, or withdrawal of CRCT.3
The STOP 2 study also had an observational arm for children receiving
CRCT whose TCD had not reverted to normal. Participation in STOP
and STOP 2 ranged from a single screening TCD to randomization.
2.2 | Post-STOP
The design of the Post-STOP study has been previously described.9 The
study was designed to follow the outcomes of children who participated
in one or both of the STOP trials. After exit fromSTOP and STOP2, these
children received TCD screening and treatment according to local prac-
tices. For all participants, the date of their last encounter in STOP or
STOP 2 defined the start of their Post-STOPobservation period.
2.3 | Data abstraction
A team of three trained data abstraction analysts visited each study
site, and reviewed all available inpatient and outpatient records for
that site's subjects. Abstraction visits occurred between January 2012
and May 2014. Retrospective data collection included information from
the subject's Post STOP start date through the date of the site visit, or
the last follow-up date for subjects no longer receiving care at that site.
Data abstraction included all TCD data, brain neuroimaging reports, and
clinical reports regarding any neurological events. Laboratory data col-
lected included results of complete blood counts and quantitation of
hemoglobin A, S and F levels (if available). Treatment data collected
included prescription of CRCT and/or hydroxyurea along with the
date(s) of administration. Using values from the written reports, all TCD
results were classified into STOP Protocol categories according to the
time averaged mean velocities in the internal carotid (ICA), middle cere-
bral arteries (MCA), or the ICA bifurcation in the following man-
ner: normal (<170 cm/s), conditional (170-199 cm/s), abnormal
(≥200 cm/s), or inadequate (readings not provided from the ICA/MCA
bilaterally in the absence of an abnormal value). For Transcranial Doppler
Imaging (TCDI), an abnormal TCD was defined as a velocity of 185 cm/s
or higher.
2.4 | STOP protocol
Annual TCD screening was recommended after the initial STOP study
for all children ages 2 to 16 years old with SCD-SS or SCD-S-β0-thal-
assemia, with more frequent TCD if the prior study was not normal.
While the interval for repeating TCD that previously was not normal
was not specified, guidance included more frequent monitoring (such
as every 3 to 6 months) for children with conditional TCD who were
at highest risk of conversion to abnormal TCD.8 Repeat TCD within
4 weeks, or initiation of CRCT, was recommended for abnormal TCD.
No specific recommendations for following inadequate TCD were
made, though alternative methods of stroke risk assessment such as
MRA were often utilized in clinical practice. The STOP protocol rec-
ommended initiation of CRCT for a confirmed abnormal TCD, or sin-
gle TCD with velocities of 220 cm/s or higher. Based on the STOP
2 study results published in 2005, the duration of CRCT was rec-
ommended to continue indefinitely.3
2.5 | Central adjudication of ischemic stroke
For adjudication of suspected strokes, two stroke neurologists inde-
pendently evaluated neuroimaging reports [magnetic resonance imag-
ing (MRI) and computerized tomography (CT)] and medical records.
They documented the clinical event while blinded to the subject's
treatment history, TCD results, and other neuroimaging results
(except studies performed at the time of the event in question). Stroke
(ischemic or hemorrhagic) was defined as any acute clinical event with
brain injury due to vascular disease. Ischemic stroke was defined
based on clinical and imaging criteria: (i) documentation in the medical
records of neurological signs and symptoms (including subtle or tran-
sient neurological events), and (ii) brain imaging evidence of infarction
in the appropriate anatomical location to explain the clinical event.
Disagreements between the reviewers were resolved through discus-
sion. Infarcts that were not associated with documented symptoms
1336 KWIATKOWSKI ET AL.
referable to the lesion were classified as silent infarcts and excluded
from this analysis.
2.6 | Assessment of STOP protocol implementation
failure
After confirmation of ischemic stroke, TCD and treatment data were
reviewed to further categorize the stroke as either failure of imple-
mentation of the STOP protocol or STOP protocol failure. Failure
of STOP protocol implementation was defined in two ways:
(i) Failure to screen appropriately with TCD, which included children
ages 2 to 16 years who had not had a TCD within 12 months, and
children older than 16 years who had not had a TCD at age 16 years
and (ii) Failure to adequately transfuse patients with abnormal TCD.
Charts were reviewed for evidence of prescription of CRCT,
including clinic notations, transfusion records, and laboratory data.
Two hematologists independently reviewed the CBC results and
hemoglobin A, S, and F quantitation to assess adherence/adequacy of
CRCT for the 6-month period prior to the stroke. Disagreements in
categorization were resolved by discussion.
The STOP study aimed to maintain the hemoglobin S level below
30% on CRCT. A subsequent report showed that outside the study
setting the hemoglobin S level often is maintained slightly higher, with
a mean of 34 ± 11% such that in the TCD with Transfusions Changing
to Hydroxyurea (TWiTCH) study, hemoglobin S levels below 45%
were not considered protocol violations.10 Therefore, we defined a
CRCT protocol violation in Post-STOP as documented Hemoglobin S
level above 45%. The CRCT treatment was first classified into one of
four categories: (i) evidence of adequate red cell transfusion defined
as the majority of hemoglobin S levels <45%; (ii) Evidence of transfu-
sion but with more than 1/3 of hemoglobin S values above 45%;
(iii) no evidence of chronic red cell transfusion and (iv) no laboratory
values available to assess adherence to transfusion. For this study,
CRCT was considered to be adequate for categories (i) and (iv) and
inadequate for categories (ii) and (iii).
Treatment with hydroxyurea was noted, but hydroxyurea was not
considered adequate therapy because the TWiTCH study was not
published until after our study end date. For subjects receiving
hydroxyurea, the CBC results and hemoglobin quantitation were
reviewed, where available. A rise in mean corpuscular volume (MCV)
of at least 10 fL from baseline, or an MCV of 93 fL or higher if pre-
hydroxyurea laboratory data were not available, and/or rise in hemo-
globin F of 10% or more were considered to represent good adher-
ence to treatment.11
The STOP protocol screen failures included subjects with stroke
who had a TCD within 12 months that was not abnormal, and sub-
jects who were beyond the age of recommended TCD screening
(17 years and older) who had a TCD at age 16 that was not abnormal.
The STOP protocol treatment failures consisted of subjects with
stroke who were receiving adequate CRCT for abnormal TCD.
2.7 | Other stroke risk factors
Additional contributing factors to stroke, including recent (within
2 weeks) hospitalization for acute chest syndrome or medical event,
history of silent infarct, and other stroke risk factors (patent foramen
ovale, acute anemic event) were assessed.1,12-14 For the group of chil-
dren with normal TCD within a year or normal TCD at 16 years old,
reports of magnetic resonance angiography at the time of, or after the
stroke, if normal, were reviewed for evidence of vessel stenosis.
2.8 | Statistical methods
Descriptive analyses including mean, median, SD, and proportions
were used to describe patient characteristics. Subjects with a his-
tory of stroke that occurred prior to the Post STOP study period
were excluded in this analysis of primary stroke. In addition, only
the first Post-STOP ischemic stroke was included in this report.
Secondary stroke rate will be reported separately. The crude inci-
dence rate of ischemic stroke was calculated as the number of first
ischemic strokes occurring during the study period, divided by the
number of person-years of observation. Follow-up was censored at
the date of ischemic stroke or the date of the last follow-up visit by
the patient.
3 | RESULTS
Nineteen of the 26 original study sites participated in Post-STOP,
contributing a total of 3539 (92%) of the STOP and STOP 2 subjects
(Figure 1). There was no significant difference in prevalence of abnor-
mal TCD between sites that did and did not participate. Of the 3539
subjects, follow-up data were available for 2851(81%). Subjects with-
out follow-up data available were significantly older at the end of
STOP (12.1 ± 4.9 years) than subjects included in Post STOP (10.51
± 4.6 years), but, there was no significant difference in the last STOP
study TCD velocities between these groups. Forty-one children who
had stroke prior to the Post-STOP study were excluded from the ana-
lyses. That included 11 children on the standard care arm in STOP,
one child on the discontinue transfusion arm in STOP 2, and
29 screened children who had stroke during the STOP study or ancil-
lary study follow-up (4/1995-11/1999). An additional two subjects
with incomplete follow-up were also excluded. Thus, 2808 subjects
were included in the analyses. Baseline characteristics of the study
population are shown in Table 1. The mean age at the start of post-
STOP was 10.5 ± 4.6 (median 10.4, range 2.0-23.2) years, and mean
duration of follow-up in post-STOP was 9.1 ± 3.4 (median 10.3, range
0-15.4) years.
3.1 | Stroke incidence
A total of 60 (2.1%) first ischemic strokes occurred during the post-
STOP study period (Figure 1). The mean age at the time of first stroke
was 13.7 (median 13.2, range 3.5 to 28.9) years. Stroke occurred at a
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F IGURE 1 Flow chart depicting Post-STOP enrollment and occurrence of ischemic stroke by TCD screening and treatment status
TABLE 1 Patient characteristics
Baselinea characteristic Total (n = 2808) Stroke (n = 60) No stroke (n = 2748) P-value*
Age (mean +/- SD), years
Age at end of STOP/STOP2 era 10.5 +/- 4.6 9.5 ± 4.1 10.5 ± 4.6 .10
Age at last TCD STOP/STOP2 era 9.6 +/- 4.2 8.7 ± 3.8 9.6 ± 4.3 .11
Sex (% female) 49.3 43.3 49.5 .35
Worst TCD category in STOP/STOP2 era (%) .0003
Abnormal 11.9 26.7 11.5
Conditional 16.9 25.0 16.7
Inadequate 6.6 6.7 6.6
Normal 64.6 41.7 65.1
Last TCD category in STOP/STOP2 era (%) <.0001
Abnormal 3.5 11.7 3.4
Conditional 11.0 21.7 10.8
Inadequate 5.6 11.7 5.4
Normal 79.9 55.0 80.5
Last STOP maximum TCD velocity (cm/s)b 144.2 +/- 28.8 160.8 ± 36.8 143.8 ± 28.6 .002
Follow-up time since last STOP/STOP2 visit, years 9.1 +/- 3.4 9.8 ± 3.1 9.1 ± 3.4 .08
Follow-up time since last STOP/STOP2 TCD, years 10.0 +/- 3.8 10.7 ± 3.8 10.0 ± 3.8 .19
aBaseline refers to last visit recorded in STOP or STOP 2.
bExcludes velocities for patients with inadequate tcd.
*P-value is for comparison of stroke versus no stroke.
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mean of 5.1 (median 3.8, range < 0.1 to 17.9) years from the last TCD.
The overall incidence of first ischemic stroke was 0.24 per 100 patient-
years (95% CI 0.18, 0.31). Patients who developed ischemic stroke
were significantly more likely to have had a history of abnormal or con-
ditional TCD than those without stroke (Table 1). Similarly, the maximal
TCD velocity and TCD category for the last study obtained in
STOP/STOP 2 was significantly higher in patients who developed
ischemic stroke than patients without stroke (Table 1).
3.2 | Relationship of stroke to STOP protocol
implementation failure
Table 2 provides the distribution of strokes based on STOP protocol
screening and treatment status. Most strokes (63%) occurred in
patients in whom the STOP protocol was not implemented correctly,
either due to lack of appropriate TCD screening or insufficient CRCT
for abnormal TCD. Twenty-three of the 60 (38%) strokes occurred in
children who were not appropriately screened with TCD. Of these
23, 17 (74%) had not had any TCD screening in the Post-STOP period
prior to the stroke. Among the 18 people in the inappropriately
screened group who had stroke at 17 years or younger (median 9.7,
range 5.4-17 years), the most recent TCD had been performed at a
median of 2.5 (range 1.2-8.3) years prior.
Among the 20 children with known abnormal TCD, only five
(25%) had evidence of adequate transfusion, and these five children
accounted for only 8.3% of the strokes in this study. Five of the
20 (25%) children with abnormal TCD had been placed on hydroxy-
urea therapy but only two had evidence of good adherence.
3.3 | Other stroke risk factors in subjects
Additional risk factors for stroke were common among children with
ischemic stroke, regardless of TCD screening status, but especially in
those subjects without known abnormal TCD (Figure 2). An episode
of acute chest syndrome within 2 weeks of the stroke occurred in
10 (17%) and recent hospitalization for other indications occurred in
an additional 14 (23%) patients.
Among patients screened with TCD within a year of the stroke, or
at age 16 years if the stroke occurred at 17 years or older, 3 of
17 (18%) had conditional or inadequate TCD at last study. Table 3
TABLE 2 Ischemic stroke by STOP protocol status (n = 60)
STOP protocol implementation
failure
38 (63%)
Not appropriately screened 23 (38%)
Last TCD >12 months
Normal 6 (10%)
Conditional 4 (7%)
Inadequate 6 (10%)
No TCD at 16 years old
(stroke at >17 years old)
Last TCD normal 6 (10%)
Last TCD conditional 1 (2%)
Abnormal TCD, not adequately
transfused
15 (25%)
No transfusion 8 (13%)
Inadequate transfusion 2 (3%)
No transfusion, on
hydroxyurea
5 (8%)
STOP protocol failure 22 (37%)
Screened appropriately,
not identified as at risk
17 (28%)
TCD within 1 year
Normal 11 (18%)
Conditional 2 (3%)
Inadequate 1 (2%)
Normal TCD at 16 years old 3 (5%)
Abnormal TCD, receiving
adequate transfusions
5 (8%)
Total 60 (100%)
F IGURE 2 Prevalence of stroke risk
factors in patients with sickle cell disease
and ischemic stroke (n = 60), stratified by
TCD screening and transfusion therapy
prior to the stroke. Other hospitalizations
were for vasoocclusive pain episode (4),
meningitis (2), bacteremia/sepsis (2),
Other infection (2), Priapism/Chronic
renal insufficiency (1), Nephrotic
syndrome (1), Steven's Johnson
Syndrome (1), Sarcoidosis (1), Heart
failure/heart transplant rejection (1),
Hypoglycemia/diabetes (1), and Deep
vein thrombosis (1)
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shows the risk factors and features of stroke among the group who
had a normal TCD within a year of the stroke. Eight of the 11 (73%)
had no significant vessel stenosis as assessed by MRA either at the
time of the stroke or afterwards. Five subjects (45%) had a history of
prior conditional (4) or inadequate (1) TCD, though the most recent
pre-stroke TCD study was normal. Other risk factors for stroke in
this group included known silent infarct in three (27%) and patent
formen ovale in one child. Five (45%) of the ischemic strokes
occurred in the setting of a recent medical illness. One subject had
cerebral sinovenous thrombosis with venous infarction that would
not be detected with TCD screening. Only two of the 11 children
were receiving treatment with hydroxyurea, and only one of these
children had evidence of good adherence with treatment. Among
the three subjects who had normal TCD at 16 years of age, stroke
occurred at 1.6, 3.9, and 6.2 years after that TCD. All three of these
subjects had recent hospitalizations (one with acute chest syn-
drome, one with vasoocclusive pain, and one with Stevens Johnson
syndrome), and one also had a documented patent foramen ovale.
Among the 23 patients whose last TCD was more than a year
before the stroke, the last TCD was conditional in 5 (22%) and inad-
equate in 6 (26%).
4 | DISCUSSION
This long-term follow-up study of children who participated in the
STOP and/or STOP 2 studies demonstrates that most ischemic stro-
kes in the Post-STOP era occurred in patients who were not managed
by the STOP protocol. This included either failure to perform TCD
screening or failure to adequately treat high-risk patients identified
through screening. These STOP protocol implementation failures
occurred despite these sites being trained in the protocol and
equipped to perform screening and treatment. It is likely that failure
to implement the STOP protocol would be more common outside of
sickle cell centers. Hence, opportunities exist for system-wide
improvements in implementation of the STOP protocol that could fur-
ther reduce stroke risk.
The STOP protocol implementation failures included deviations
from both TCD screening and treatment recommendations. Among
ischemic strokes 38% occurred in children who had not been screened
with TCD in the past year, despite almost half (11/23) of these chil-
dren's last TCD study being conditional or inadequate. We previously
showed that the overall rates of TCD re-screening at the STOP and
STOP 2 study sites were surprisingly low, with only 57% of children
having evidence of at least one follow-up TCD.9 Our current analyses
support that failure to screen properly leads to preventable stroke.
We also found that CRCT implementation failures occur. Three quar-
ters of children in this study with abnormal TCD who developed
stroke were not receiving adequate CRCT that could have prevented
this outcome.
In this study, we are unable to assess reasons for the lack of full
implementation of the STOP protocol. System level factors, such as
limited TCD equipment or lack of appropriately trained personnelT
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could have influenced successful implementation. However, patient or
family factors such as poor adherence to screening and lack of accep-
tance of chronic transfusion also may have contributed. Complications
of transfusion, such as alloimmunization and iron overload may also
limit the feasibility of continuing a chronic transfusion protocol. Wide
variability in screening rates at the sites, with some sites able to
achieve 90% re-screen rate,9 indicates that patient factors do not pre-
vent some centers from appropriately re-screening the majority of
patients. Addressing system levels factors, therefore, might be suc-
cessful in enhancing implementation.
The Post-STOP study took place prior to the publication of the
TWiTCH study, which showed that hydroxyurea therapy for children
with abnormal TCD without significant vasculpathy was noninferior
to transfusions at maintaining TCD velocities, a surrogate marker for
control of stroke risk.15 Thus, it is possible that as hydroxyurea use
becomes more widespread for primary stroke prevention in the
future, acceptance of and adherence with long-term treatment might
be improved. Nonetheless, in this study, only two of five subjects with
stroke who had been placed on hydroxyurea had evidence of ade-
quate adherence, suggesting that methods to improve treatment
adherence are imperative. In addition, stroke occurred in two subjects
in our study with abnormal TCD with good adherence to hydroxyurea.
In a French cohort of children, 29% of children with abnormal TCD
who had developed normal TCD velocities on regular transfusions
reverted to high-risk TCD after being switched to hydroxyurea.16
Thus, it is likely that long-term hydroxyurea therapy will not be ade-
quate prophylactic therapy for a subset of children.
Nonetheless, limitations to the STOP protocol exist as 28% of ische-
mic strokes in this cohort occurred in children who were not identified by
TCD screening as being high-risk. This does not generally appear to be a
failure of TCD to identify significant intracranial vasculopathy, as the
majority of children with recent normal TCD had no evidence of
vasculopathy by MRA. It is possible that some of the STOP screening fail-
ures could be due to the presence of extracranial vasculopathy that is
associated with increased stroke risk,17 which would not be detected by
the STOP TCD protocol. Future studies to assess the value of adding scan-
ning of the extracranial ICA to the STOP TCD protocol are needed. How-
ever, in this cohort, TCD screening did miss moderate or high-grade
stenosis in two of 12 subjects with stroke (Table 3), perhaps because short
segment stenosis can be missed or collateral vessels may be insonated.
Another possible reason for ischemic stroke occurrence in the setting
of appropriate STOP screening is that the stroke occurred secondary to
risk factors other than vasculopathy detectable by TCD. Additional risk
factors for stroke were present in a significant proportion of patients in
this cohort who had stroke. Over half (57%) of the strokes in subjects
with normal TCD in the past year (5 of 11) or at 16 years old (all 3),
occurred in the setting of a recent medical illness. Baseline cerebral blood
flow velocity is elevated in SCD to compensate for anemia and cerebral
vasoreactivity is reduced,18 predisposing to ischemia in the setting of
acute blood pressure changes, worsening anemia, or hypoxemia that can
accompany acute medical events. Careful attention to control of oxygen-
ation and blood pressure and correction of severe anemia in patients
with SCD in the setting of acute illnesses may further help to reduce
stroke occurrence in this patient population. Among the group with a
recent normal TCD who experienced stroke, evidence of prior silent
cerebral infarct was present in three patients. Silent cerebral infarct is a
known risk factor for stroke that may be attenuated with regular red cell
transfusions.14,19 Patent foramen ovale, a risk factor for stroke in the
general population, was also present in two subjects, which could be
amenable to repair. Thus addressing other known stroke risk factors
might further reduce the incidence of stroke in children and young adults
with sickle cell disease.
Finally, 8% of the strokes occurred in children with known abnor-
mal TCD who were receiving adequate transfusion therapy. This failure
rate is not surprising given that the risk of recurrent stroke has been
reported to be approximately 20% with transfusions.12 Further studies
to better identify these high-risk children and the potential benefit of
alternative interventions such as hematopoietic stem cell transplanta-
tion or adjunctive antiplatelet therapies for this population are needed.
The Post-STOP study has many strengths. These follow-up data
were obtained on a large, multicenter cohort who had baseline stan-
dardized stroke risk assessments as part of a clinical trial. The medical
care was obtained from sickle cell centers trained in the STOP proto-
col, which should have enhanced protocol implementation. A trained
abstraction team visited each site and utilized consistent data collec-
tion tools across sites, and stroke outcomes were centrally adjudi-
cated. Nonetheless, limitations to the study exist. Chart review may
miss evidence of screening or treatment not recorded in the chart.
Stroke adjudications were based on imaging reports only; we were
not able to collect actual imaging studies and hence could not reliably
distinguish arterial versus venous distribution of the infarcts. Com-
plete laboratory data often were missing, which impacted the ability
to determine adequacy of treatment. In subjects with abnormal TCD
reported to be receiving red cell transfusions but without available
laboratory data, we assumed that transfusion therapy was adequate,
which may have underestimated the effectiveness of the STOP proto-
col. Lastly, only about half of the participating centers had integrated
pediatric and adult medical records, which limited information on
stroke occurrence after transition to adult care.
In conclusion, Post-STOP confirms a reduction in ischemic stroke after
dissemination of the STOP Protocol that has been reported in other stud-
ies. Unfortunately, these data also confirm that the STOP Protocol is often
inadequately implemented, although the reasons for this are not clear.
Although most of the ischemic strokes that occurred in these experienced
centers were associated with inadequate screening or therapeutic imple-
mentation, some strokes were documented in the absence of
vasculopathy and were not predicted by TCD or prevented by treatment,
suggesting that not all stroke in SCD is preventable by the STOP protocol,
and that additional strategies might further reduce stroke rates. This study
indicates that there remain substantial opportunities for ischemic stroke
prevention by more complete implementation of the STOP Protocol.
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